EUCTR2008-000983-17-IT进行中（未招募）不适用
Diagnostic procedure with 68Ga-labelled somatostatin analogues in tumours presumably expressing SSTR2 and/or 5 receptors, to be evaluated for treatment with the same analogues labelled with 90Y o 177Lu - ND
AZIENDA OSPEDALIERA ARCISPEDALE S. MARIA NUOVA0 个研究点开始时间: 2008年3月21日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients in need of the diagnostic procedure described above will be appointed by the endocrinological, oncological, medical or other centres or wards, or other hospitals, with the clinical information necessary to evaluate its appropriateness; the final decision shall be taken by the Nuclear Physician after an accurate evaluation of each patient?s clinical situation.
- •In respect to the actual laws, the patient will be properly informed on the procedure and objectives of the scan, and asked to give written consent.
- •§Patients of both sexes aged > 18 (for patients younger a specific authorisation will be submitted to this Ethics Committee), with histologically documented primitive tumour presumably expressing SSTR2 and/or 5: the main clinical question will be research of metastatic lesions in presence of a rise of specific markers or of symptoms due to hormonal incretion in productive neoplasms; in cases of advanced or metastatic disease, 68Ga DOTATOC or 68GaDOTATATE PET scan may be used as a preliminary step for treatment with the analogues labelled with beta- emitters; not only neuroendocrine tumours, but also thyroid, breast pulmonary SCLC and brain neoplasms shall be considered, these forms being susceptible to the above mentioned treatment only if positive to the diagnostic scan.
- •§Patients? consent to take part in the study, with written consent
- •In case of female patients in fertile age, the procedure will be performed exclusively in presence of a negative pregnancy test.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Pregnancy (breast feeding will be interrupted)
研究者
相似试验
进行中（未招募）
不适用
se of 68Ga-DOTA-NOC for the evaluation of patients with Idiopathic pulmonary fibrosisSTUDY CODE: 68Ga-DOTA-NOC/ILD 01/2008 - 68Ga-DOTA-NOC/ILD01/2008EUCTR2008-007168-40-ITAZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
已完成
不适用
Pilot Study – Use of [68Ga] gallium-labelled Prostate Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) for the Characterisation of Metastatic Lesions in Patients with Renal Cell CarcinomaACTRN12615000854538Dr Simon Wood10
尚未招募
不适用
â??Use of Gallium-68PET-CT in the Diagnosis and Follow-up of patients with Prostate Cancerâ??CTRI/2018/07/014933International Atomic Energy Agency
进行中（未招募）
1 期
Evaluation of diagnostic accuracy of [68Ga]Ga-PSMA-11 PET/CT in primary staging of Intermediate and High Risk Prostatic Cancer in men newly diagnosedMen with histo-pathological confirmation of PCa with intermediate or high-risk disease according to 2019 Prostate Cancer EAU Guidelines Risk Group StratificationMedDRA version: 21.1Level: LLTClassification code 10036927Term: Prostate neoplasiaSystem Organ Class: 100000004864EUCTR2019-004685-18-ITAZIENDA OSPEDALIERO-UNIVERSITARIA DI MODENA100
进行中（未招募）
不适用
EVALUATION OF DIAGNOSTIC ACCURACY OF 68GA-CITRATE PET/CT IN PATIENTS WITH INFLAMMATORY-INFECTIOUS DISEASES. - NDEUCTR2007-005373-58-ITAZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI